Business Context and Reporting Period
Akebia Therapeutics, Inc. (AKBA) filed a Current Report on Form 8-K dated January 29, 2024. The filing details the entry into a new senior secured term loan facility and the termination of a prior loan agreement to restructure the company's debt obligations.
Key Financial Metrics and Transaction Details
- New Debt Facility: Entered into a $55.0 million senior secured term loan facility with Kreos Capital VII (UK) Limited.
- Initial Funding: An initial tranche of $37.0 million was funded on the closing date, yielding net proceeds of approximately $34.5 million after costs.
- Future Tranches: Up to $18.0 million remains available in two tranches ($8.0 million and $10.0 million), contingent on FDA approval of vadadustat and equity raise milestones.
- Interest Rate: Floating rate based on SOFR (1-month) plus 6.75% margin, with a 4.25% floor and 15.00% cap.
- Warrant Issuance: Issued warrants to purchase 3,076,923 shares at an exercise price of $1.30 per share; an additional 1,153,846 warrants are issuable upon the drawdown of Tranche C.
- Financial Covenants: Must maintain cash equivalents of at least $15.0 million OR generate $150.0 million in trailing twelve-month revenue.
Material Changes Versus Prior Period
- Debt Restructuring: The company repaid in full its prior term loan facility with Pharmakon, including termination fees, using proceeds from the new Kreos facility.
- Liquidity Impact: The transaction provided immediate liquidity of approximately $34.5 million in net cash proceeds.
- Capital Structure: The company now holds a secured debt obligation with a maturity date of March 31, 2025, extendable to January 29, 2028, contingent on regulatory milestones.
Outlook, Risks, and Contingencies
- Regulatory Contingency: The availability of future loan tranches and the extension of the maturity date to 2028 are strictly conditioned on receiving FDA approval for vadadustat by June 30, 2024.
- Repayment Acceleration Risk: If FDA approval is not obtained by June 30, 2024, the interest-only period ends on October 1, 2024, triggering mandatory principal repayments over seven months.
- Prepayment Penalties: Prepayment is subject to premiums ranging from 1.0% to 4.0%, plus a requirement to pay interest for the following 12 months if prepaid within the first year.
- Security Interest: All obligations are secured by a first-priority lien on substantially all existing and after-acquired assets.
Investor Verification Checklist
- Verify the company's current cash balance against the $15.0 million minimum covenant requirement.
- Monitor the FDA review timeline for vadadustat to assess the risk of repayment acceleration in October 2024.
- Review the dilution impact of the 3,076,923 warrants issued at $1.30 per share.
- Confirm the status of any planned equity raises required to unlock the $10.0 million Tranche C loan.